Christophe Arbet-Engels, MD, Q10: Possibility of Combination Drugs with Empagliflozin

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions. 

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources